Cold-EEZE continues brand transformation
This article was originally published in The Tan Sheet
Executive Summary
ProPhase Labs hires media solutions firm Women's Marketing Inc. to develop and implement multimedia campaigns for the Cold-EEZE and Kids-EEZE lozenge brands. Doylestown, Pa.-based ProPhase additionally announced details for its Kids-EEZE line extension of symptom-specific chews, including Allergy, Chest Congestion and Cough/Cold formulas. ProPhase already is revising its existing products' packaging and flavors (1"The Tan Sheet" May 24, 2010, In Brief). "We are excited to join with WMI to create a dynamic media campaign that will introduce our new and improved products to new consumers and reinvigorate our loyal customers," ProPhase CEO Ted Karkus said Sept. 7
You may also be interested in...
ProPhase pares costs, preps relaunches
The OTC firm, formerly known as Quigley, discontinues a candy product line and shutters a contract manufacturing facility, reducing first-quarter operating costs and expenses 51 percent to $2.2 million. ProPhase Labs' net sales in the January-March period also dropped 50.4 percent to $2 million, but its year-over-year net loss was halved to $1.1 million. Sales took a hit as retailer orders of cold and flu products, such as ProPhase's Cold-EEZE zinc lozenges, were front-loaded in fourth quarter 2009, according to CEO Ted Karkus. He added May 17 ProPhase is entering "a wonderful new phase," with redesigned packaging, a new mint frost Cold-EEZE flavor and the planned reintroduction of a Kids-EEZE non-liquid product line (1"The Tan Sheet" May 10, 2010, In Brief)
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.